country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189262

Copy Link Print Information

Multitarget AD-IN-8

Multitarget AD-IN-8 is a blood-brain barrier-penetrant, orally active multitarget inhibitor. Multitarget AD-IN-8 inhibits abnormal Tau phosphorylation at Thr181 and Ser396 sites and attenuates NF-κB phosphorylation. Multitarget AD-IN-8 downregulates BACE1 expression to reduce Aβ production, inhibits the Bax/Bcl-2 pathway, and suppresses Caspase-1 activation. Multitarget AD-IN-8 attenuates p38, ERK1/2, and JNK phosphorylation and inhibits Aβ_25-35-induced Apoptosis. Multitarget AD-IN-8 exhibits neuroprotective effects against Aβ_25-35-induced injury, ameliorates learning and memory deficits in AD mouse models, and alleviates hippocampal neuronal pathological damage. Multitarget AD-IN-8 can be used for research on Alzheimer's disease.

For research use only. We do not sell to patients.

Formula: C₃₁H₃₄N₂O₈
Molecular Weight:562.61

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Multitarget AD-IN-8 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

BACE1

Bax

Bcl-2

Caspase-1

ERK1

ERK2

All NF-κB Isoforms :

All Beta-secretase Isoforms :

BACE1
BACE2

All Bcl-2 Family Isoforms :

All Caspase Isoforms :

All p38 MAPK Isoforms :

All ERK Isoforms :

All JNK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
PC-12	EC50	1.24 μM	Neuroprotective activity against Aβ_25-35-induced injury in PC12 cells assessed as increase in cell viability incubated for 24 hrs by CCK-8 assay. Neuroprotective activity against Aβ_25-35-induced injury in PC12 cells assessed as increase in cell viability incubated for 24 hrs by CCK-8 assay.	42628381

In Vitro

Multitarget AD-IN-8 (Compound S12) (20 μM) demonstrates potent neuroprotective activity against Aβ_25-35 induced injury in PC12 cells with an EC₅₀ of 1.24 μM^[1].
Multitarget AD-IN-8 (5-20 μM; 1 h pretreatment and 24 h Aβ_25-35 exposure) suppresses the aberrant phosphorylation of tau protein at Thr181 and Ser396 in PC12 cells^[1].
Multitarget AD-IN-8 (5-20 μM; 1 h pretreatment and 24 h Aβ_25-35 exposure) inhibits the Aβ_25-35 induced activation of the NF-κB signaling pathway in PC12 cells^[1].
Multitarget AD-IN-8 (5-20 μM; 1 h pretreatment and 24 h Aβ_25-35 exposure) suppresses Aβ_25-35 induced activation of the MAPK signaling pathway in PC12 cells^[1].
Multitarget AD-IN-8 (5-20 μM; 1 h pretreatment and 24 h Aβ_25-35 exposure) inhibits the production of BACE1 in PC12 cells induced by Aβ_25-35^[1].
Multitarget AD-IN-8 (5-20 μM; 1 h pretreatment and 24 h Aβ_25-35 exposure) inhibits the activation of the Bax/Bcl-2 pathway and suppresses caspase-1 activation in PC12 cells^[1].
Multitarget AD-IN-8 (20 μM; 24 h) effectively suppresses Aβ_25-35 induced apoptosis in PC12 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

PC12
Concentration:

5-20 μM
Incubation Time:

1 h (pretreatment); 24 h (Aβ_25-35 exposure)
Result:

Markedly attenuated Aβ_25-35 induced hyperphosphorylation of tau at Thr181 and Ser396 residues.
Inhibited the relative protein expression of p-Tau (Thr181)/Total-Tau and p-Tau (Ser396)/Total-Tau.\nAt a concentration of 20 μM, significantly attenuated Aβ_25-35 induced phosphorylation of NF-κB.
Exhibited greater inhibitory activity than both donepezil and UA.\nAttenuated the Aβ_25-35 induced upregulation of p-p38/p38, p-ERK1/2/ERK1/2, and p-JNK/JNK.\nMarkedly attenuated the Aβ_25-35 induced BACE1 upregulation.\nAttenuated the Aβ_25-35 induced upregulation of the Bax/Bcl-2 ratio and caspase-1 expression.

Apoptosis Analysis^[1]

Cell Line:

PC12
Concentration:

20 μM
Incubation Time:

24 h
Result:

Reduced the percentage of apoptotic PC12 cells to 11%, compared to the Aβ_25-35 group which had an apoptosis rate of 35.2%.

In Vivo

Multitarget AD-IN-8 (12.5-50 mg/kg; i.g.; daily; 21 consecutive days) ameliorates Aβ₂₅-₃₅-induced cognitive dysfunction in AD model mice, including impairments in working memory, visual recognition, and spatial memory, and effectively alleviates neuronal pathological damage in the hippocampus^[1].
Multitarget AD-IN-8 (12.5-50 mg/kg; i.g.; daily; 20 consecutive days) exhibits no overt toxicity in major organs including the heart, liver, spleen, and kidneys in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR mice (Male, 20-25 g)^[1]
Dosage:

12.5, 25, 50 mg/kg
Administration:

i.g.; daily; 21 consecutive days
Result:

Ameliorated the alternation behavior deficit in the Y-maze test.
Increased the discrimination index (DI) and preference index (PI) at 1 h and 24 h in the novel object recognition test.
Decreased escape latency and swimming distance in the Morris water maze, with the 50 mg/kg group differing significantly from the model group.
Increased time spent in and distance traveled within the target quadrant in the spatial probe test, with the 50 mg/kg group showing the most pronounced improvement.
Resulted in a more organized neuronal architecture and significantly attenuated neuronal damage in both the CA1 and CA3 regions.

Animal Model:

ICR mice (Male)^[1]
Dosage:

12.5, 25, 50 mg/kg
Administration:

i.g.; daily; 20 consecutive days
Result:

No abnormal behavior, mortality, or clinically significant changes in body weight were observed.
HE staining of major organs (heart, liver, spleen, and kidney) showed no obvious pathological lesions in all groups.

Related Protocols :

Chemical Information

Molecular Weight 562.61
Formula C₃₁H₃₄N₂O₈
SMILES

CC(C1=C(O)C(C)=C(O)C([C@@]2(C)C(/C3=C(NC4=CC=C(OC(N(CCC)CCC)=O)C=C4)/C)=O)=C1OC2=CC3=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Quan YS, et al. Design synthesis and evaluation of usnic acid derivatives as multi-target drugs for Alzheimer's disease. Bioorganic chemistry. 2026 Oct 05;181:110398.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Multitarget AD-IN-8

All NF-κB Isoforms

All Beta-secretase Isoforms

All Bcl-2 Family Isoforms

All Caspase Isoforms

All p38 MAPK Isoforms

All ERK Isoforms

All JNK Isoforms